Optically Active Antifungal Azoles. XII. Synthesis and Antifungal Activity of the Water-Soluble Prodrugs of 1-[(1R,2R)-2-(2,4-Difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-3-[4-(1H-1-tetrazolyl)phenyl]-2-imidazolidinone.
作者:Takashi ICHIKAWA、Tomoyuki KITAZAKI、Yoshihiro MATSUSHITA、Masami YAMADA、Ryogo HAYASHI、Masashi YAMAGUCHI、Yutaka KIYOTA、Kenji OKONOGI、Katsumi ITOH
DOI:10.1248/cpb.49.1102
日期:——
1-[(1R, 2R)-2-(2, 4-Difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1, 2, 4-triazol-1-yl)propyl]-3-[4-(1H-1-tetrazolyl)phenyl]-2-imidazolidinone (1: TAK-456) was selected as a candidate for clinical trials, but since its water-solubility was insufficient for an injectable formulation, the quaternary triazolium salts 2 were designed as water-soluble prodrugs. Among the prodrugs prepared, 4-acetoxymethyl-1-[(2R, 3R)-2-(2, 4-difluorophenyl)-2-hydroxy-3-[2-oxo-3-[4-(1H-1-terazolyl)phenyl]-1-imidazolidinyl]butyl]-1H-1, 2, 4-triazolium chloride (2a: TAK-457) was selected as an injectable candidate for clinical trials based on the results of evaluations on solubility, stability, hemolytic effect and in vivo antifungal activities.
1-[(1R, 2R)-2-(2, 4-二氟苯基)-2-羟基-1-甲基-3-(1H-1, 2, 4-三唑-1-基)丙基]-3-[4-(1H-1-四唑基)苯基]-2-咪唑啉酮(1: TAK-456)被选为临床试验候选药物,但由于其水溶性不足,无法制备注射剂,因此设计了季铵三唑盐2作为水溶性前药。在制备的前药中,4-乙酰氧甲基-1-[(2R, 3R)-2-(2, 4-二氟苯基)-2-羟基-3-[2-氧代-3-[4-(1H-1-四唑基)苯基]-1-咪唑啉基]丁基]-1H-1, 2, 4-三唑氯化物(2a: TAK-457)根据溶解性、稳定性、溶血效应和体内抗真菌活性的评估结果,被选为注射剂候选药物进行临床试验。